BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
BioAtla (BCAB), a clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics for solid tumors, will host a conference call and webcast on November 7, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results and business highlights. The financial results press release will be available before the conference call on the company's website. A replay will be accessible through the Investors section.
BioAtla (BCAB), una società biofarmaceutica in fase clinica che sviluppa terapie anticorpali biologiche attivamente condizionali per tumori solidi, ospiterà una conferenza telefonica e un webcast il 7 novembre 2024, alle 16:30 ET per discutere i risultati finanziari del terzo trimestre 2024 e i principali aspetti aziendali. Il comunicato stampa sui risultati finanziari sarà disponibile prima della conferenza telefonica sul sito web della società. Una registrazione sarà accessibile attraverso la sezione Investitori.
BioAtla (BCAB), una empresa de biotecnología en etapa clínica que desarrolla terapias anticuerpos biológicos condicionalmente activas para tumores sólidos, llevará a cabo una llamada de conferencia y un webcast el 7 de noviembre de 2024, a las 4:30 p.m. ET para discutir sus resultados financieros del tercer trimestre de 2024 y aspectos destacados del negocio. El comunicado de prensa sobre los resultados financieros estará disponible antes de la llamada de conferencia en el sitio web de la empresa. Una grabación estará accesible a través de la sección de Inversores.
BioAtla (BCAB), 고형 암을 위한 조건부 활성 생물학적 항체 치료제를 개발 중인 임상 단계의 생명공학 회사는 2024년 11월 7일 오후 4시 30분 ET에 전화 회의 및 웹캐스트를 개최하여 2024년 3분기의 재무 결과 및 사업 하이라이트를 논의할 예정입니다. 재무 결과에 대한 보도 자료는 회사 웹사이트에서 전화 회의 전에 제공될 것입니다. 녹음은 투자자 섹션을 통해 접근할 수 있습니다.
BioAtla (BCAB), une entreprise de biotechnologie en phase clinique développant des thérapeutiques anticorps biologiques activement conditionnels pour les tumeurs solides, organisera une conférence téléphonique et un webinaire le 7 novembre 2024 à 16h30 ET pour discuter de ses résultats financiers du troisième trimestre 2024 et des points forts de son activité. Le communiqué de presse sur les résultats financiers sera disponible avant la conférence téléphonique sur le site web de l'entreprise. Un enregistrement sera accessible dans la section Investisseurs.
BioAtla (BCAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das bedingt aktive biologischen Antikörpertherapeutika für solide Tumoren entwickelt, wird am 7. November 2024 um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die finanziellen Ergebnisse des dritten Quartals 2024 sowie geschäftliche Höhepunkte zu besprechen. Die Pressemitteilung zu den finanziellen Ergebnissen wird vor der Telefonkonferenz auf der Unternehmenswebsite verfügbar sein. Eine Aufzeichnung wird im Bereich für Investoren zugänglich sein.
- None.
- None.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights.
Conference Call and Webcast Information
Date: Thursday, November 7, 2024
Time: 4:30 p.m. ET
Webcast Link: BioAtla Third Quarter 2024 Earnings Conference Call
Dial-in Numbers: (800) 343-4136 (domestic), (203) 518-9848 (international)
Conference ID: BIOATLA
The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When will BioAtla (BCAB) report Q3 2024 earnings?
How can investors access BioAtla's (BCAB) Q3 2024 earnings call?
Where can investors find BioAtla's (BCAB) Q3 2024 financial results?
